• ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

    Source: Nasdaq GlobeNewswire / 07 Aug 2024 08:01:10   America/Chicago

    SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 2024 Wedbush PacGrow Healthcare Conference being held August 13-14, 2024 in New York City. Company management will participate in one-on-one meetings with investors on Wednesday, August 14, 2024.

    About ARS Pharmaceuticals, Inc.
    ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing neffy (also referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit www.ars-pharma.com.

    ARS Investor Contacts:
    Justin Chakma
    ARS Pharmaceuticals
    justinc@ars-pharma.com

    ARS Media Contact:
    Christy Curran
    Sam Brown Inc.
    christycurran@sambrown.com


    Primary Logo

Share on,